Publications

BibTex format

@article{Sharrack:2020:10.1038/s41409-019-0684-0,
author = {Sharrack, B and Saccardi, R and Alexander, T and Badoglio, M and Burman, J and Farge, D and Greco, R and Jessop, H and Kazmi, M and Kirgizov, K and Labopin, M and Mancardi, G and Martin, R and Moore, J and Muraro, PA and Rovira, M and Sormani, MP and Snowden, JA and European, Society for Blood and Marrow Transplantation EBMT Autoimmune Diseases Working Party ADWP and the Joint Accreditation Committee of the International Society for Cellular Therapy ISCT and EBMT JACIE},
doi = {10.1038/s41409-019-0684-0},
journal = {Bone Marrow Transplantation},
pages = {283--306},
title = {Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE).},
url = {http://dx.doi.org/10.1038/s41409-019-0684-0},
volume = {55},
year = {2020}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - These updated EBMT guidelines review the clinical evidence, registry activity and mechanisms of action of haematopoietic stem cell transplantation (HSCT) in multiple sclerosis (MS) and other immune-mediated neurological diseases and provide recommendations for patient selection, transplant technique, follow-up and future development. The major focus is on autologous HSCT (aHSCT), used in MS for over two decades and currently the fastest growing indication for this treatment in Europe, with increasing evidence to support its use in highly active relapsing remitting MS failing to respond to disease modifying therapies. aHSCT may have a potential role in the treatment of the progressive forms of MS with a significant inflammatory component and other immune-mediated neurological diseases, including chronic inflammatory demyelinating polyneuropathy, neuromyelitis optica, myasthenia gravis and stiff person syndrome. Allogeneic HSCT should only be considered where potential risks are justified. Compared with other immunomodulatory treatments, HSCT is associated with greater short-term risks and requires close interspeciality collaboration between transplant physicians and neurologists with a special interest in these neurological conditions before, during and after treatment in accredited HSCT centres. Other experimental cell therapies are developmental for these diseases and patients should only be treated on clinical trials.
AU  - Sharrack,B
AU  - Saccardi,R
AU  - Alexander,T
AU  - Badoglio,M
AU  - Burman,J
AU  - Farge,D
AU  - Greco,R
AU  - Jessop,H
AU  - Kazmi,M
AU  - Kirgizov,K
AU  - Labopin,M
AU  - Mancardi,G
AU  - Martin,R
AU  - Moore,J
AU  - Muraro,PA
AU  - Rovira,M
AU  - Sormani,MP
AU  - Snowden,JA
AU  - European,Society for Blood and Marrow Transplantation EBMT Autoimmune Diseases Working Party ADWP and the Joint Accreditation Committee of the International Society for Cellular Therapy ISCT and EBMT JACIE
DO  - 10.1038/s41409-019-0684-0
EP  - 306
PY  - 2020///
SN  - 0268-3369
SP  - 283
TI  - Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE).
T2  - Bone Marrow Transplantation
UR  - http://dx.doi.org/10.1038/s41409-019-0684-0
UR  - https://www.ncbi.nlm.nih.gov/pubmed/31558790
UR  - https://www.nature.com/articles/s41409-019-0684-0
UR  - http://hdl.handle.net/10044/1/74606
VL  - 55
ER  -

Download

ProfessorPaoloMuraro

Contact

Assistant

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)